Images List Premium Download Classic

Immune Response

Immune Response-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Markers of immune response
Stallergenes
August 17, 2017 - N°20170233816

The present invention concerns methods for determining if a dendritic cell is a type 2 dendritic cell or a tolerogenic dendritic cell, methods for determining if a patient undergoing immunotherapy, and/or who has been administered with a vaccine, is developing an immune response oriented either towards a regulatory t cell response or towards an effector type 2 cell response, and methods ...
Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
Idera Pharmaceuticals, Inc.
August 17, 2017 - N°20170233741

The invention provides novel immune regulatory oligonucleotides (iro) as antagonist of tlrs and methods of use thereof. These iros have unique sequences that inhibit or suppress tlr-mediated signaling in response to a tlr ligand or tlr agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, ...
Antibody therapeutics that bind ctla4
Sorrento Therapeutics, Inc.
August 17, 2017 - N°20170233476

There is disclosed compositions and methods relating to or derived from anti-ctla4 antibodies. More specifically, there is disclosed fully human antibodies that bind ctla4, ctla4-antibody binding fragments and derivatives of such antibodies, and ctla4-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, ...
Immune Response Patent Pack
Download 464+ patent application PDFs
Immune Response Patent Applications
Download 464+ Immune Response-related PDFs
For professional research & prior art discovery
inventor
  • 464+ full patent PDF documents of Immune Response-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
University Of Miami
August 17, 2017 - N°20170233448

Various methods and compositions are provided which can be employed to modulate the immune system. Compositions include a fusion protein comprising: (a) a first polypeptide comprising interleukin-2 (il-2) or a functional variant or fragment thereof; and (b) a second polypeptide, fused in frame to the first polypeptide, wherein the second polypeptide comprises an extracellular domain of interleukin-2 receptor alpha (il-2...
Recombinant hiv-1 envelope proteins and their use
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv
August 17, 2017 - N°20170233441

Hiv-1 env ectodomain trimers stabilized in a prefusion mature closed conformation and methods of their use and production are disclosed. In several embodiments, the hiv-1 env ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to hiv-1 in a subject. In additional embodiments, the therapeutically effective amount of the hiv-1 env ectodomain trimers can ...
Vaccines having an antigen and interleukin-21 as an adjuvant
The Trustees Of The University Of Pennsylvania
August 17, 2017 - N°20170232100

Disclosed herein is a vaccine comprising an antigen and il-21. Also disclosed herein are methods for increasing an immune response in a subject. The methods may comprise administering the vaccine to the subject in need thereof.
Immune Response Patent Pack
Download 464+ patent application PDFs
Immune Response Patent Applications
Download 464+ Immune Response-related PDFs
For professional research & prior art discovery
inventor
  • 464+ full patent PDF documents of Immune Response-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Novel antigen for use in malaria
Camris International, Inc.
August 17, 2017 - N°20170232091

The present invention provides polypeptides useful as antigens expressed at the pre-erythrocytic stage of the malaria parasite. The antigens can be utilized to induce an immune response and sterile protection against malaria in a mammal by administering the antigens in vaccine formulations or expressing the antigens in dna or other recombinant protein expression systems delivered as a vaccine formulation.
Multi-indication mrna cancer immunotherapy
Morphogenesis, Inc.
August 17, 2017 - N°20170232090

Synthetic bacterial messenger rna can be used to prepare autologous, allogenic or direct nucleic acid cancer vaccines. Cancer cells are transfected either in vitro or in vivo with mrna obtained from dna that encodes an immunogenic bacterial protein. An immune response to the cancer is generated from direct administration of the mrna in vivo or administration of vaccines prepared from ...
Treatment of inflammatory and dysimmune response
Chu De Dijon
August 10, 2017 - N°20170226480

A drug and, more particularly, to a drug for treating inflammatory and dysimmune response. The present invention also relates to a drug for treating graft-versus-host disease. Thus, the present invention relates in particular to a cell expressing cd33, cd11b, cd14, cd163, cd206, hla-dr, cd44, cd31, ccr5 and cd105.
Disease therapy by inducing immune response to trop-2 expressing cells
Ibc Pharmaceuticals, Inc.
August 10, 2017 - N°20170226219

The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for trop-2 (egp-1) and at least one binding site for cd3. The bispecific antibodies are of use for inducing an immune response against a trop-2 expressing tumor, such as carcinoma of the esophagus, pancreas, lung, stomach, colon, rectum, urinary bladder, breast, ovary, ...
Method for in vivo expansion of t regulatory cells
University Of Miami
August 10, 2017 - N°20170226218

Compositions specific for tnf-receptor superfamily member 25 (tnfrsf25, dr3) modulate the immune response by regulating t regulatory cells.
Antibody therapeutics that bind cd137
Sorrento Therapeutics, Inc.
August 10, 2017 - N°20170226215

There is disclosed compositions and methods relating to or derived from anti-cd137 antibodies. More specifically, there is disclosed fully human antibodies that bind cd137, cd137-antibody binding fragments and derivatives of such antibodies, and cd137-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, ...
An anti-cd45rc antibody for use as drug
UniversitÉ De Nantes
August 10, 2017 - N°20170226209

The invention relates to an isolated anti-cd45rc antibody for use in preventing or treating transplant rejection, autoimmune diseases, unwanted immune responses against proteins expressed in the course of gene therapy and/or therapeutic proteins, allergy as well as lymphoma or cancer which are associated with cd45rc+ cells. The invention relates to an isolated anti-cd45rc antibody for use ...
Immune Response Patent Pack
Download 464+ patent application PDFs
Immune Response Patent Applications
Download 464+ Immune Response-related PDFs
For professional research & prior art discovery
inventor
  • 464+ full patent PDF documents of Immune Response-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Adenocarcinoma antigenic determinants and methods
Vaccinogen, Inc.
August 10, 2017 - N°20170226171

Adenocarcinoma antigenic determinants, methods for their production and use, and broadly-specific human monoclonal antibodies reactive to the epitopes. These epitopes, which can be physically recapitulated, are conserved across a range of adenocarcinomas and are capable of eliciting an immune response in humans.
Vaccine adjuvant compositions
Children's Medical Center Corporation
August 10, 2017 - N°20170224811

Embodiments described herein relate to combinatorial compositions and uses thereof, for example, as vaccine adjuvant compositions, for enhancing immune response, for inducing differentiation of nave t cells to differentiate into ifn-γ-producing t cells, and for preventing and treating infections. The combinatorial composition comprises tlr and clr agonists. The combinatorial composition comprises at least one tlr4 agonist and ...
Therapeutic compositiojns and methods for inducing an immune response to herpes simplex virus type 2 (hsv-2)
Admedus Vaccines Pty Ltd
August 10, 2017 - N°20170224808

Disclosed are therapeutic compositions and methods for inducing an immune response to herpes simplex virus type 2 (hsv-2). More particularly, the invention relates to a method for inducing an immune response in a subject by introducing and expressing an hsv gd2-encoding dna vaccine.
Recombinant bacterium and methods of antigen and nucleic acid delivery
The Arizona Board Of Regents For And On Behalf Of Arizona State University
August 10, 2017 - N°20170224806

The present invention provides a recombinant bacterium and methods of using the recombinant bacterium to induce an immune response.
Carrier molecule for antigens
Glaxosmithkline Biologicals Sa
August 10, 2017 - N°20170224803

The invention provides a conjugate comprising an antigen and a carrier molecule, wherein the carrier molecule comprises a bp-2a antigen and a spb1 antigen. Bp-2a and spb1 are streptococcus agalactiae antigens. The conjugate may be used in a method for raising an immune response in a mammal, the method comprising administering the conjugate to the mammal. Also provided ...
Cancer therapy using a vaccine in combination with a cell-based immunotherapeutic agent
Xeme Biopharma Inc.
August 10, 2017 - N°20170224797

A cancer therapy composition and a method of cancer treatment by inducing humoral and cellular immune responses against cancer cells in a patient is provided. The method includes administering to the patient a therapeutically effective amount of a vaccine, wherein the vaccine includes at least one tumor-associated antigen, at least one immunostimulant, and at least one lipid capable of forming ...
Therapeutic cancer vaccine containing tumor-associated neoantigens and immunostimulants in a delivery system
Xeme Biopharma Inc.
August 10, 2017 - N°20170224796

A therapeutic vaccine and a method of cancer treatment by inducing humoral and cellular immune responses against malignant cells is provided. The vaccine comprises a delivery system that incorporates at least one peptide whose sequence encompasses a genetic mutation associated with a malignancy (neoantigen), at least one immunostimulant, and at least one type of lipid molecule.
Cdca1 epitope peptides for th1 cells and vaccines containing the same
Oncotherapy Science, Inc.
August 10, 2017 - N°20170224795

Isolated cdca1-derived epitope peptides having th1 cell inducibility are disclosed herein. Such peptides can be recognized by mhc class ii molecules and induce th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to mhc class ii molecules and induce cdca1-specific cytotoxic t lymphocytes (ctls) in addition to th1 cells. Such peptides are ...
Loading